Tumor angiogenesis (scientific article (publication date: 8 May 2008))

cites work (P2860)

Q42399225	A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
Q92465156	A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b
Q38662419	A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
Q30839218	A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis.
Q33576606	A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo
Q39817181	A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
Q54238539	A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer.
Q39051468	A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis
Q47143379	A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma
Q35798191	A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor
Q37520919	A novel in vivo vascular imaging approach for hierarchical quantification of vasculature using contrast enhanced micro-computed tomography
Q28476695	A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis
Q53201697	A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.
Q33861319	A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Q33401450	A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
Q35116704	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
Q35879889	A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
Q37513843	A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Q35584707	A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
Q34961777	A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
Q37119876	A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
Q36958387	A prostate-specific antigen-dependent fusion polypeptide inhibits growth of prostate cancer cells in vitro and in vivo
Q35917810	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Q34164735	A review on various targeted anticancer therapies
Q42869599	A role for vascular deficiency in retinal pathology in a mouse model of ataxia-telangiectasia
Q38010295	A roundabout way to cancer
Q84070923	A study of pipeline drugs in neuroendocrine tumors
Q34703792	A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients.
Q30433214	A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.
Q35131244	A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis
Q59059617	A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours
Q64089185	ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway
Q28286119	ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity
Q36021172	AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis
Q42269997	ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis
Q34334378	Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression
Q37981960	Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer.
Q48194235	Accelerated growth of hemangioblastoma in pregnancy: the role of proangiogenic factors and upregulation of hypoxia-inducible factor (HIF) in a non-oxygen-dependent pathway
Q84933381	Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
Q38241953	Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era.
Q91857825	Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies
Q37993772	Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma
Q35063138	Activation of cytosolic phospholipase A2 downstream of the Src-phospholipase D1 (PLD1)-protein kinase C γ (PKCγ) signaling axis is required for hypoxia-induced pathological retinal angiogenesis
Q61798295	Activator of G-protein signaling 8 is involved in VEGF-induced choroidal neovascularization
Q34464168	Activin receptor inhibitors--dalantercept
Q36161541	Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer
Q57190003	Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo
Q34095979	Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Q37492442	Adjuvant and neoadjuvant therapy in renal cell carcinoma
Q33693793	Adrenomedullin as a therapeutic target in angiogenesis
Q37434663	Advances in meningioma therapy
Q82866392	Advances in ovarian cancer disease control
Q37655420	Advances in radionuclide molecular imaging in myocardial biology
Q33410375	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch
Q35377689	Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin
Q34635176	Aflibercept in the treatment of metastatic colorectal cancer
Q38414962	Age-related properties of the tumour vasculature in renal cell carcinoma
Q40663333	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes
Q35002247	An adsorptive transfer technique coupled with brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics.
Q30443142	An experimental research into endostatin microbubble combined with focused ultrasound for anti-tumor angiogenesis in colon cancer
Q53489426	An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models.
Q33691759	Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Q89514362	Angiocrine endothelium: from physiology to cancer
Q47218543	Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
Q38160129	Angiogenesis and acute myeloid leukemia
Q37800804	Angiogenesis and breast cancer.
Q37330675	Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer
Q37479382	Angiogenesis and pituitary tumors
Q33520467	Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data
Q37504362	Angiogenesis as a therapeutic target in malignant gliomas
Q38389975	Angiogenesis in cancer: Anti-VEGF escape mechanisms
Q37963379	Angiogenesis in head and neck cancer: a review of the literature
Q26853604	Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
Q34611189	Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.
Q38468107	Angiogenesis in salivary gland tumors: from clinical significance to treatment.
Q51301228	Angiogenesis in spontaneous tumors and implications for comparative tumor biology.
Q37435385	Angiogenesis in the treatment of non-small cell lung cancer
Q57139434	Angiogenesis inhibitors in the treatment of prostate cancer
Q35783911	Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
Q37703520	Angiogenesis: What can it offer for future medicine?
Q37413352	Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma
Q36611297	Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients
Q36782590	Angiomirs expression profiling in diffuse large B-Cell lymphoma
Q39034717	Angiopoietin pathway gene expression associated with poor breast cancer survival
Q36183887	Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword
Q24655930	Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy
Q36330281	Anti-VEGF therapies in the clinic
Q53202606	Anti-VEGF therapy in pituitary carcinoma.
Q50689698	Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.
Q37031917	Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
Q28538098	Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles
Q37622551	Anti-angiogenesis agents in metastatic or recurrent cervical cancer
Q39512686	Anti-angiogenesis by lentivirus-mediated small interfering RNA silencing of angiopoietin-2 gene in pancreatic carcinoma
Q39210287	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Q38891146	Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model
Q89100360	Anti-angiogenic activity of Middle East medicinal plants of the Lamiaceae family
Q38020234	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future
Q38115596	Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment
Q34788355	Anti-angiogenic effect of the total flavonoids in Scutellaria barbata D. Don
Q90091009	Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling
Q36557403	Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs
Q26826817	Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives
Q48196734	Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI.
Q33770680	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Q93336666	Anti-angiogenic therapy for high-grade glioma
Q40705444	Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).
Q34088265	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Q60609594	Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF
Q33733451	Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2
Q37434674	Anti-vascular endothelial growth factor therapy for malignant glioma
Q38757723	Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility
Q48876380	Antiangiogenesis: biology and utility in the treatment of gliomas
Q33572395	Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine
Q37112714	Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma
Q38748970	Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies
Q46291408	Antiangiogenic properties of caudatin in vitro and in vivo by suppression of VEGF‑VEGFR2‑AKT/FAK signal axis
Q51013825	Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways.
Q37533652	Antiangiogenic strategies for treatment of malignant gliomas
Q38264310	Antiangiogenic therapies for glioblastoma
Q37614203	Antiangiogenic therapies for high-grade glioma
Q45820306	Antiangiogenic therapies: is VEGF-A inhibition alone enough?
Q36563542	Antiangiogenic therapy for cancer: an update
Q34145245	Antiangiogenic therapy for glioblastoma
Q24193485	Antiangiogenic therapy for high-grade glioma
Q38725587	Antiangiogenic therapy in oncology: current status and future directions
Q35966757	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
Q38672966	Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Q39287099	Antiangiogenics and immunotherapies in cervical cancer: an update and future's view
Q38103583	Antibody-based therapy in colorectal cancer
Q54469699	Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Q37373102	Antimetastatic activity of novel ruthenium (III) pyridine complexes
Q89665975	Antitumor Effects of Trimethylellagic Acid Isolated From Sanguisorba officinalis L. on Colorectal Cancer via Angiogenesis Inhibition and Apoptosis Induction
Q33638344	Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment
Q33563034	Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice.
Q34097326	Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential
Q37706985	Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism
Q28388238	Arginine ADP-ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway
Q36746133	Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma
Q64057935	Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer
Q50993734	Assessment of MiRNA Regulation of Endothelial Progenitor Cell Mediated Angiogenesis.
Q34105344	Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat
Q45905154	Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model.
Q34990498	Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis
Q36638595	Association of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in North Indian patients.
Q92604610	Association of pregnancy-associated plasma protein A and vascular endothelial growth factor with pregnancy-induced hypertension
Q90663359	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial
Q39925764	Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.
Q38682453	Autophagy, a double-edged sword in anti-angiogenesis therapy
Q37696994	Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production
Q28116976	Axl is essential for VEGF-A-dependent activation of PI3K/Akt
Q36764845	BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS
Q34059649	BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
Q38818713	Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Q54496082	Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Q38234567	Barriers to drug delivery in solid tumors
Q37478709	Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target?
Q39782817	Bevacizumab and its use in epithelial ovarian cancer
Q38081238	Bevacizumab as front-line treatment for newly diagnosed epithelial cancer
Q38111265	Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
Q38003707	Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Q38654464	Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect
Q43225608	Bevacizumab for advanced breast cancer
Q38706483	Bevacizumab for the treatment of cervical cancer.
Q38129428	Bevacizumab for the treatment of glioblastoma
Q91830356	Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
Q37994752	Bevacizumab in endometrial cancer treatment
Q38216007	Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.
Q42677492	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Q34132928	Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
Q37415131	Bevacizumab toxicities and their management in ovarian cancer
Q37784672	Bevacizumab: current updates in treatment
Q36881812	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy
Q35216301	Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
Q35111538	Bioluminescence reporter gene imaging characterize human embryonic stem cell-derived teratoma formation
Q37114675	Biomarker in Colorectal Cancer.
Q39929142	Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology
Q37132680	Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice
Q26778891	Biomarkers of Angiogenesis in Colorectal Cancer
Q26774580	Biomarkers of cancer angioprevention for clinical studies
Q34673567	Biomarkers of response and resistance to antiangiogenic therapy
Q37815281	Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Q51826314	Blood flow and endothelial cell phenotype regulation during sprouting angiogenesis.
Q37846342	Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?
Q37328390	Blood-based biomarkers for the optimization of anti-angiogenic therapies
Q50182712	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.
Q41866817	Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
Q42176147	Bone marrow-derived cells serve as proangiogenic macrophages but not endothelial cells in wound healing
Q36831312	Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.
Q37982803	Bone marrow-derived proangiogenic cells in pancreatic cancer.
Q38781397	Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy
Q37409487	CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis
Q33630819	CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Q24296427	CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo
Q39303901	CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties
Q36100430	CDP-diacylglycerol synthetase-controlled phosphoinositide availability limits VEGFA signaling and vascular morphogenesis.
Q54576039	CK2 functionally interacts with AKT/PKB to promote the β-catenin-dependent expression of survivin and enhance cell survival.
Q33734694	COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis
Q38981326	COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models.
Q39300421	CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy
Q30432791	CXC chemokines in cancer angiogenesis and metastases
Q34069720	CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy
Q35516144	Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells
Q38160757	Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma
Q52723400	Cancer Cell Mechanics: Adhesion G Protein-coupled Receptors in Action?
Q22242276	Cancer genome landscapes
Q37496849	Cancer invasion and metastasis: interacting ecosystems.
Q26796292	Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity
Q33961287	Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death
Q37610682	Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis
Q30854226	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer
Q36891574	Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery
Q44228500	Cardio-oncology: it takes two to translate
Q35584182	Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies
Q39717717	Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer
Q37474070	Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Q39497289	Celastrus orbiculatus extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo
Q33913432	Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy
Q37505664	Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51.
Q57810087	Cell death in cancer in the era of precision medicine
Q35603983	Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis
Q35123591	Cell-based quantification of molecular biomarkers in histopathology specimens
Q58575098	Cellular and Molecular Heterogeneity Associated with Vessel Formation Processes
Q41251561	Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
Q37546027	Cervical cancer therapy: current, future and anti-angiogensis targeted treatment
Q33525581	Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma
Q38554663	Changing paradigms in the systemic treatment of advanced cervical cancer
Q98385780	Characteristic Blood-Perfusion Reduction of Walker 256 Tumor Induced by Diagnostic Ultrasound and Microbubbles
Q55463722	Characteristics of tumour vessels in cytological squash smears of astrocytic tumours
Q57116617	Characterization and potential roles of bone marrow-derived stromal cells in cancer development and metastasis
Q57185834	Characterization of receptor binding kinetics for vascular endothelial growth factor-A using SPR
Q30438032	Chemokines as mediators of neovascularization
Q38053441	Chemotherapy: What is its role in meningioma?
Q38800593	Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments
Q39687326	Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance.
Q35078406	Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects
Q37780014	Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.
Q53420162	Circulating endothelial cells in chronic lymphocytic leukemia: more evidence of disturbed angiogenesis.
Q50784041	Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance.
Q54628938	Circulating perivascular progenitors: a target of PDGFR inhibition.
Q42546774	Classifier of cross talk genes predicts the prognosis of hepatocellular carcinoma
Q36884393	Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer
Q34658366	Clinical advances in the development of novel VEGFR2 inhibitors
Q42708261	Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
Q37892591	Clinical trials of vaccines for immunotherapy in pancreatic cancer
Q26785665	Clinical utility of ramucirumab in advanced gastric cancer
Q39388167	Coevolution of the tumor microenvironment revealed by quantum dot-based multiplexed imaging of hepatocellular carcinoma
Q83192661	Colonic anastomosis and colonic polyp mucosal metastasis of signet ring cell gastric adenocarcinoma
Q33803564	Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
Q92945264	Combination of Epigallocatechin-3-gallate and Silibinin: A Novel Approach for Targeting Both Tumor and Endothelial Cells
Q39320160	Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Q36684023	Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma
Q57317511	Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma
Q90074156	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Q89791281	Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis
Q34105997	Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
Q41231221	Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
Q91658406	Competing Fluid Forces Control Endothelial Sprouting in a 3-D Microfluidic Vessel Bifurcation Model
Q38717558	Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity
Q38058289	Concise review: genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy
Q27023510	Contemporary use of bevacizumab in ovarian cancer
Q34341736	Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth
Q36100725	Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans
Q44556811	Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis
Q47675953	Controlling Differentiation of Stem Cells for Developing Personalized Organ-on-Chip Platforms.
Q36003149	Coup d'Etat: an orphan takes control.
Q38166329	Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.
Q26801289	Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
Q38840543	Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR.
Q93039741	Current Development of Monoclonal Antibodies in Cancer Therapy
Q34204524	Current approaches and recent developments in the management of head and neck paragangliomas
Q53225923	Current opinion on bevacizumab on endometrial cancer treatment.
Q34198939	Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model
Q38169761	Current status of antiangiogenic therapies for glioblastomas
Q35742534	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Q58546808	Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer
Q37900650	Cytokines in neuroblastoma: from pathogenesis to treatment.
Q35880529	Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells
Q33603626	DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA
Q40346499	DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer
Q49932201	Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol
Q64079790	Deciphering the Pharmacological Mechanism of the Herb in the Treatment of Nasopharyngeal Carcinoma by Integrating iTRAQ-Coupled 2-D LC-MS/MS Analysis and Network Investigation
Q35713658	Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma
Q39456092	Delta-like ligand 4-notch blockade and tumor radiation response
Q34427294	Delta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma
Q48541561	Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma
Q50073578	Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.
Q84529564	Design, synthesis, and anti-proliferative evaluation of [1,1'-biphenyl]-4-ols as inhibitor of HUVEC migration and tube formation
Q41852958	Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology
Q30475052	Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks
Q39432968	Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue
Q34300621	Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
Q39411007	Diabetes and Wound Angiogenesis
Q38062793	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Q43245707	Did animal offer relevant model for Bevacizumab testing?
Q35053270	Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis
Q35803027	Differential macrophage programming in the tumor microenvironment
Q39092622	Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Q37507568	Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer
Q37204589	Dihydroartemisinin induces endothelial cell anoikis through the activation of the JNK signaling pathway.
Q39459741	Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
Q37260920	Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Q93166626	Discovery of Pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors
Q64064629	Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies
Q36212825	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
Q30373777	Disruption of Prostate Microvasculature by Combining Microbubble-Enhanced Ultrasound and Prothrombin.
Q52619579	Disruption of tumor neovasculature by microbubble enhanced ultrasound: a potential new physical therapy of anti-angiogenesis.
Q34141587	Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis
Q38192670	Do anti-angiogenic cancer therapies increase risk of significant weight loss?
Q36659012	Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.
Q42021890	Does CD34 Staining Reflect the Angiogenic Process in the Bone Marrow? An Analysis of a Series of Chronic Myeloid Leukemia Patients
Q46193990	Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
Q39226994	Dose dependent effects of cadmium on tumor angiogenesis.
Q33786674	Downregulation of angiogenesis factors, VEGF and PDGF, after rapid IgE desensitization and oral immunotherapy in children with food allergy
Q37050403	Dynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model
Q38171740	Dysphonia induced by anti-angiogenic compounds
Q38160089	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
Q24310236	EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF
Q38019814	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
Q52149377	Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
Q43201120	Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes.
Q33947163	Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells
Q36503239	Effect of CPU-XT-008, a combretastatin A-4 analogue, on the proliferation, apoptosis and expression of vascular endothelial growth factor and basic fibroblast growth factor in human umbilical vein endothelial cells
Q31060162	Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature
Q53239742	Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.
Q37126585	Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
Q37458674	Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer
Q49693392	Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature
Q26826864	Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension
Q34668740	Effects of tetrahydrocurcumin on hypoxia-inducible factor-1α and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice.
Q90455818	Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
Q28079362	Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
Q90400076	Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis
Q38230556	Efficacy of motesanib diphosphate in non-small-cell lung cancer
Q40600188	Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial
Q33800886	Efficient in vivo selection of a novel tumor-associated peptide from a phage display library
Q47855049	Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer
Q28536420	Embedding synthetic microvascular networks in poly(lactic acid) substrates with rounded cross-sections for cell culture applications
Q58798211	Emerging Medical Treatments for Meningioma in the Molecular Era
Q38065241	Emerging VEGF-receptor inhibitors for colorectal cancer
Q45874449	Emerging drugs for head and neck cancer
Q35098322	Emerging drugs to treat squamous cell carcinomas of the head and neck
Q48171089	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications
Q35914897	Emerging insights into the molecular and cellular basis of glioblastoma
Q38132645	Emerging paradigms in cardiomyopathies associated with cancer therapies
Q41837594	Emerging role of multikinase inhibitors for refractory thyroid cancer
Q34660607	Emerging therapeutic targets for synovial sarcoma
Q36519807	Emerging treatments for choroidal metastases
Q39431959	Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan
Q36821570	Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
Q39415229	Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression
Q55506580	Endogenous Matrix-Derived Inhibitors of Angiogenesis.
Q45901060	Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.
Q58093810	Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway
Q42047188	Endostatin and anastellin inhibit distinct aspects of the angiogenic process
Q38821715	Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression
Q28547399	Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis
Q36499423	Endothelial Cords Promote Tumor Initial Growth prior to Vascular Function through a Paracrine Mechanism
Q33680346	Endothelial Membrane Remodeling Is Obligate for Anti-Angiogenic Radiosensitization during Tumor Radiosurgery
Q35255024	Endothelial cell tube formation assay for the in vitro study of angiogenesis
Q33592677	Endothelial cell-derived interleukin-6 regulates tumor growth
Q34777219	Endothelial cell-initiated extravasation of cancer cells visualized in zebrafish
Q34473290	Endothelial cells provide a notch-dependent pro-tumoral niche for enhancing breast cancer survival, stemness and pro-metastatic properties
Q36498075	Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling
Q35857778	Endothelial progenitor cells carrying monocyte markers are selectively abnormal in type 1 diabetic patients with early retinopathy
Q37957761	Endothelial progenitor cells: current issues on characterization and challenging clinical applications
Q38930761	Engineered Microvessels for the Study of Human Disease
Q48822702	Enhancement of Antiangiogenic Efficacy of Iron(II) Complex by Selenium Substitution
Q97543137	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
Q37153834	EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
Q38207484	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors
Q33619401	Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma
Q39836194	Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population
Q28307353	Epsin Family of Endocytic Adaptor Proteins as Oncogenic Regulators of Cancer Progression
Q38708078	Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature
Q90701568	Erythropoietin in tumor angiogenesis
Q36685121	Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.
Q64254117	Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure
Q28539181	Evaluating the potential bioactivity of a novel compound ER1626
Q37965053	Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging
Q34470473	Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging
Q38081233	Everolimus in colorectal cancer
Q50878183	Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence.
Q21145736	Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent
Q37862235	Evolving strategies: future treatment of glioblastoma
Q37501570	Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction.
Q64234892	Exogenous sickle erythrocytes combined with vascular disruption trigger disseminated tumor vaso-occlusion and lung tumor regression
Q38709057	Exosomes from Plasmodium-infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model
Q39120436	Exploring and challenging the network of angiogenesis.
Q39497632	Exploring the concept of "inflammatory angiogenesis" in keratocystic odontogenic tumor
Q38319730	Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer
Q42376380	Expression and association of VEGF-Notch pathways in infantile hemangiomas
Q46042271	Expression and correlation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis
Q39697040	Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue
Q33951007	Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
Q37158416	Expression of VEGF, its receptors, and HIF-1α in Dupuytren's disease
Q44753855	Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density
Q33410553	Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy
Q95660964	Extracellular vesicles from genetically unstable, oncogene-driven cancer cells trigger micronuclei formation in endothelial cells
Q34129824	FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol
Q34439734	Fast rearrangement of the neuronal growth cone's actin cytoskeleton following VEGF stimulation
Q38799374	Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties.
Q45370083	Feasibility study of CT perfusion imaging for prostate carcinoma
Q54634525	Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.
Q39725148	Firefly luciferase-based dynamic bioluminescence imaging: a noninvasive technique to assess tumor angiogenesis
Q38213500	First-line and maintenance therapy for ovarian cancer: current status and future directions
Q33591948	Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope
Q35866398	Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization.
Q24314412	Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
Q51366224	Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
Q37174213	Foxc2 transcription factor as a regulator of angiogenesis via induction of integrin beta3 expression
Q24653645	Foxc2 transcription factor: a newly described regulator of angiogenesis
Q26827148	From sprouting angiogenesis to erythrocytes generation by cancer stem cells: evolving concepts in tumor microcirculation
Q37326863	Future of targeted agents in metastatic colorectal cancer
Q35230245	G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist
Q37149710	G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
Q24631249	GLO1-A novel amplified gene in human cancer
Q35597134	Gas challenge-blood oxygen level-dependent (GC-BOLD) MRI in the rat Novikoff hepatoma model
Q36629538	Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications
Q36764284	Gene regulation by RNA binding proteins and microRNAs in angiogenesis
Q58362653	Gene therapy in peripheral artery disease
Q55058836	Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.
Q34645999	General aspects of colorectal cancer
Q38565301	Genetic markers of recurrence in colorectal cancer
Q84340559	Genetic pathways linking hemostasis and cancer
Q41945502	Genetic reduction of vascular endothelial growth factor receptor 2 rescues aberrant angiogenesis caused by epsin deficiency
Q33620506	Genetics of glioblastoma: a window into its imaging and histopathologic variability
Q29417061	Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3
Q59465394	Genomically personalized therapy in head and neck cancer
Q38700575	Ginseng Metabolites on Cancer Chemoprevention: An Angiogenesis Link?
Q42835218	Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2.
Q39959730	Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype
Q58883666	Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis
Q39030742	Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing neovasculature after local irradiation
Q37962333	HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Q35097628	HIF-1α and HIF-2α: siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation
Q44102393	HIF-1α expression correlates with cellular apoptosis, angiogenesis and clinical prognosis in rectal carcinoma
Q96231688	Heart-derived fibroblasts express LYPD-1 and negatively regulate angiogenesis in rat
Q33526297	Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells
Q45128040	Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis
Q55224564	High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Q54569303	High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Q40421447	High-Resolution Intravital Microscopy of Tumor Angiogenesis
Q35312455	High-field small animal magnetic resonance oncology studies.
Q54631831	Hippocampal Neurogenesis after Traumatic Brain Injury Is Mediated by Vascular Endothelial Growth Factor Receptor-2 and the Raf/MEK/ERK Cascade
Q34399444	Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Q42321106	Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation
Q35767922	Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma
Q37291680	Host-derived tumor endothelial marker 8 promotes the growth of melanoma
Q35588157	How platelets safeguard vascular integrity
Q34640644	Hyperplasia of pericytes is one of the main characteristics of microvascular architecture in malignant glioma
Q37996791	Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation
Q42426199	Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies
Q37428993	Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model
Q35825993	Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma
Q38078802	Hypoxia-regulated microRNAs in human cancer
Q39530204	IL-3 is a novel target to interfere with tumor vasculature
Q35987440	IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma
Q35043619	Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues
Q35165550	Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand
Q37338152	Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay
Q40867070	Identification of a Peptide from In vivo Bacteriophage Display with Homology to EGFL6: A Candidate Tumor Vasculature Ligand in Breast Cancer
Q33364892	Identification of a characteristic vascular belt zone in human colorectal cancer
Q39390836	Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array
Q48128395	Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.
Q35138135	Immunity and immune suppression in human ovarian cancer
Q37898427	Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy
Q37417622	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research
Q33357295	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?
Q37280829	Immunotherapy in colorectal cancer
Q35840873	Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
Q37825180	In pursuit of new anti-angiogenic therapies for cancer treatment
Q27301905	In vitro and in vivo anti-angiogenic activities of Panduratin A
Q90568470	In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells
Q37222836	In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors
Q38480926	In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes
Q36149661	In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued
Q37662388	Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis
Q34445829	Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis
Q35757896	Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas
Q44864734	Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer
Q81985539	Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Q36642689	Increased expression of placental growth factor in high-grade endometrial carcinoma
Q55425422	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
Q26776198	Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features
Q42183046	Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling.
Q37194653	Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation
Q47386049	Infantile hemangioma: pathogenesis and mechanisms of action of propranolol
Q34443672	Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in China
Q40372513	Influence of Exposure to Chronic Persistent Low-Dose Ionizing Radiation on the Tumor Biology of Clear-Cell Renal-Cell Carcinoma. An Immunohistochemical and Morphometric Study of Angiogenesis and Vascular Related Factors
Q37577918	Influence of obesity on breast cancer receptor status and prognosis
Q37854731	Influence of the tumor microenvironment on angiogenesis
Q33959754	Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors
Q37958925	Inhibition of angiogenesis and the angiogenesis/invasion shift
Q93087611	Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy
Q36476333	Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis
Q33915046	Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth
Q38284055	Inhibition of the VEGF signalling pathway and glomerular disorders.
Q42051818	Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo
Q26859210	Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity
Q34658016	Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model
Q55643012	Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
Q34152009	Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors
Q28483727	Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA
Q42025842	Insufficient radiofrequency ablation promotes human hepatoma SMMC7721 cell proliferation by stimulating vascular endothelial growth factor overexpression
Q53068289	Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.
Q38341324	Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer
Q41670949	Integrins as Therapeutic Targets: Successes and Cancers.
Q35446009	Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
Q35627827	Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
Q33860350	Intravitreal itraconazole inhibits laser-induced choroidal neovascularization in rats.
Q41928551	Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy
Q38340008	Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.
Q37826096	Invited review: decoding the microRNA response to hypoxia.
Q39658278	Involvement of Osteopontin in the Matrix-Degrading and Proangiogenic Changes Mediated by Nicotine in Pancreatic Cancer Cells
Q42643167	Isolation and characterization of three new anti-proliferative Sesquiterpenes from Polygonum barbatum and their mechanism via apoptotic pathway.
Q24297342	Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion
Q35966791	Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer
Q28544728	JSI-124 suppresses invasion and angiogenesis of glioblastoma cells in vitro
Q49309017	Kaempferol Inhibits Angiogenesis by Suppressing HIF-1α and VEGFR2 Activation via ERK/p38 MAPK and PI3K/Akt/mTOR Signaling Pathways in Endothelial Cells
Q35760920	Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC).
Q51375392	Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Q89907643	Lentivirus-Mediated VEGF Knockdown Suppresses Gastric Cancer Cell Proliferation and Tumor Growth in vitro and in vivo
Q38702994	Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Q57789067	LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning
Q47417663	Lipocalin-type prostaglandin D synthase-derived PGD2 attenuates malignant properties of tumor endothelial cells
Q91782756	Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules
Q35213093	Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure
Q47170227	LncRNA SUMO1P3 drives colon cancer growth, metastasis and angiogenesis
Q33623357	Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye.
Q42366666	Long non-coding RNAs associated with non-small cell lung cancer
Q36782557	Long noncoding RNA Hotair mediated angiogenesis in nasopharyngeal carcinoma by direct and indirect signaling pathways
Q47181473	Long-Term Effects of Weight Loss and Exercise on Biomarkers Associated with Angiogenesis
Q37435219	Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
Q38027711	Lung cancer: microRNA and target database
Q35832959	Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.
Q37057680	Lymphatic endothelial cells support tumor growth in breast cancer
Q37821374	Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors
Q38134562	Lysyl oxidase in colorectal cancer
Q28280138	Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis
Q42368143	MEF2 transcription factors are key regulators of sprouting angiogenesis
Q39736118	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Q47112808	MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.
Q37955105	Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.
Q50266714	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Q52682124	Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy.
Q47773621	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
Q37363751	Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
Q36170252	Management of antiangiogenic therapy-induced hypertension
Q33849034	Management of stage IV rectal cancer: palliative options
Q37621006	Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds
Q41437410	Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.
Q82415696	Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1
Q49476941	Mechanism of the anti-angiogenic effect of Avemar on tumor cells
Q34972161	Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates
Q38233448	Medical management of meningiomas
Q37785808	Medical therapies for meningiomas
Q38683133	Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases
Q35038893	Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies
Q42631326	Melanoma topology reveals a stem-like phenotype that promotes angiogenesis.
Q82973923	Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies
Q92522555	Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation
Q57490984	Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial
Q37763502	Metronomic chemotherapy: new rationale for new directions
Q36210881	MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma
Q46131735	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression
Q47118717	MiR-205/YAP1 in Activated Fibroblasts of Breast Tumor Promotes VEGF-independent Angiogenesis through STAT3 Signaling
Q43560853	MicroRNA-144-3p suppresses tumor growth and angiogenesis by targeting SGK3 in hepatocellular carcinoma
Q39184127	MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42.
Q33918344	MicroRNA-22 regulates hypoxia signaling in colon cancer cells
Q47616223	MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway
Q84598420	MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression
Q34422270	MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling
Q38247982	MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Q37363641	MicroRNAs: opening a new vein in angiogenesis research.
Q36520345	MicroRNA‑126 inhibits proliferation and metastasis by targeting pik3r2 in prostate cancer
Q34165754	Microfluidic culture models of tumor angiogenesis
Q48443748	Microvessel density is high in clear-cell renal cell carcinomas of Ukrainian patients exposed to chronic persistent low-dose ionizing radiation after the Chernobyl accident
Q36766681	Mifepristone improves chemo-radiation response in glioblastoma xenografts.
Q34562257	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies
Q38514734	Modeling and analyzing gene co-expression in hepatocellular carcinoma using actor-semiotic networks and centrality signatures.
Q42132001	Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models
Q34383803	Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues
Q37039546	Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles
Q92945523	Molecular Modeling-Based Delivery System Enhances Everolimus-Induced Apoptosis in Caco-2 Cells
Q92835893	Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma
Q34089123	Molecular diversity of VEGF-A as a regulator of its biological activity.
Q38168618	Molecular markers and targeted therapies for adrenocortical carcinoma
Q94452251	Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
Q36500108	Molecular targeting of liposomal nanoparticles to tumor microenvironment
Q37736281	Molecular therapeutic targets for glioma angiogenesis
Q38272728	Molecularly targeted therapies for recurrent glioblastoma: current and future targets
Q38002719	Molecularly targeted therapies in cervical cancer. A systematic review
Q37861547	Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents
Q33740232	Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
Q37142916	Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways
Q34774917	Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth
Q36335923	Motif mimetic of epsin perturbs tumor growth and metastasis
Q39203569	Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
Q37086837	Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer
Q38645392	Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.
Q38119471	Multifunctional nanomicellar systems for delivering anticancer drugs.
Q26821959	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Q37404422	Multiscale models of breast cancer progression
Q37758250	Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation.
Q57283011	NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
Q37043370	NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
Q90185375	NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
Q39440633	NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation
Q38933699	Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Q37695537	Natriuretic peptide receptor A signaling regulates stem cell recruitment and angiogenesis: a model to study linkage between inflammation and tumorigenesis.
Q41383985	Neovascularization in Glioblastoma: Current Pitfall in Anti-angiogenic therapy
Q90060268	Network Pharmacology-based Investigation of the Underlying Mechanism of Panax Notoginseng Treatment of Diabetic Retinopathy
Q33873686	Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma
Q42719160	Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons
Q37503510	Neuronal control of metabolism through nutrient-dependent modulation of tracheal branching
Q90292756	New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment
Q37752435	New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future
Q24619151	New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer
Q49800025	New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications
Q34224278	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors
Q33956040	New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab.
Q26739049	New trends in molecular and cellular biomarker discovery for colorectal cancer
Q34086332	New vessel formation in peritumoral area of squamous cell carcinoma of the head and neck
Q38059265	Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
Q47160725	Nitidine chloride acts as an apoptosis inducer in human oral cancer cells and a nude mouse xenograft model via inhibition of STAT3.
Q34309479	Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways
Q52665696	Non-angiogenic tumours and their influence on cancer biology.
Q37036792	Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond
Q39202040	Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways
Q47303044	Notch transactivates Rheb to maintain the multipotency of TSC-null cells
Q33745300	Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth
Q28546583	Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays
Q37325086	Novel anti-angiogenic therapies for malignant gliomas
Q41897121	Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Q38714205	Novel roles of folic acid as redox regulator: Modulation of reactive oxygen species sinker protein expression and maintenance of mitochondrial redox homeostasis on hepatocellular carcinoma
Q38221292	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation
Q47701879	Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.
Q38107793	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?
Q38113988	Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy
Q35882341	Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin
Q33441574	Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan
Q26749333	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction
Q38004740	Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Q34165780	Oxygen-controlled three-dimensional cultures to analyze tumor angiogenesis
Q33778804	P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis
Q39433494	PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells
Q34122706	PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization.
Q37650308	Palliative treatment of unresectable metastatic colorectal cancer
Q41876722	Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats.
Q28535447	Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma
Q37730633	Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.
Q37974693	Pazopanib for the treatment of breast cancer
Q28269229	Pazopanib in the treatment of soft tissue sarcoma
Q52672956	Pazopanib radio-sensitization of human sarcoma tumors.
Q37550249	Perfusion computed tomography in colorectal cancer: protocols, clinical applications and emerging trends.
Q24595357	Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression
Q47128300	Periodic microstructures of blood capillaries revealed by synchrotron X-ray multi-resolution microscopic analysis
Q37730440	Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy
Q26996793	Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
Q64983729	Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle.
Q35108333	Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
Q37401839	Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors
Q33627763	Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
Q90449579	Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Q91719723	Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer
Q37234829	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Q64230340	Phosphatase Actin Regulator-1 (PHACTR-1) Knockdown Suppresses Cell Proliferation and Migration and Promotes Cell Apoptosis in the bEnd.3 Mouse Brain Capillary Endothelial Cell Line
Q54595475	Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of β-catenin transcriptional activity.
Q36944511	Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer
Q38743706	PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Q36268182	PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors
Q38881266	Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis.
Q27026940	Positron emission tomography to assess hypoxia and perfusion in lung cancer
Q36024383	Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion
Q33557565	Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole
Q34128953	Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer
Q54542173	Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.
Q34388847	Practicing pathology in the era of big data and personalized medicine
Q35797850	Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma
Q39046994	Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma
Q43950404	Primary tumorectomy promotes angiogenesis and pulmonary metastasis in osteosarcoma-bearing nude mice
Q39336606	Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation.
Q36520616	Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
Q26775134	Profile of nintedanib in the treatment of solid tumors: the evidence to date
Q41869300	Profiling of microRNAs in AML cells following overexpression or silencing of the VEGF gene
Q38308001	Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer
Q35664735	Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors
Q84801828	Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival
Q36241849	Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis
Q50358087	Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis
Q51501402	Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells.
Q42404762	Proliferation and tissue remodeling in cancer: the hallmarks revisited
Q99212442	Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma
Q39512060	Protein kinase CK2 promotes cancer cell viability via up-regulation of cyclooxygenase-2 expression and enhanced prostaglandin E2 production
Q48538797	Protein neddylation and its alterations in human cancers for targeted therapy
Q36953182	Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway
Q38814218	RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature
Q37804904	Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Q33605773	Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting
Q51651776	Raiders of the lost mark - endothelial cells and their role in transplantation for hematologic malignancies.
Q92635779	Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
Q38826507	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
Q26745418	Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
Q38842754	Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies
Q34446310	Ramucirumab: preclinical research and clinical development.
Q30438696	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
Q38252759	Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
Q38108392	Recent advances in the treatment of metastatic renal cell carcinoma
Q58756849	Recent advances in understanding the complexities of metastasis
Q21092930	Recent advances of novel targeted therapy in non-small cell lung cancer
Q64103672	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Q58607138	Receptor Tyrosine Kinase-Targeted Cancer Therapy
Q64069367	Recombinant RGD-disintegrin DisBa-01 blocks integrin αβ and impairs VEGF signaling in endothelial cells
Q47869837	Recombinant protein rMBP-NAP restricts tumor progression by triggering antitumor immunity in mouse metastatic lung cancer
Q50277288	Red Raspberry Phenols Inhibit Angiogenesis: A Morphological and Subcellular Analysis Upon Human Endothelial Cells
Q37301807	Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma
Q33791749	Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.
Q42288643	Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma
Q28513991	Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis
Q64375116	Regulation of vascularization by hypoxia-inducible factor 1
Q26991865	Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment
Q37334087	Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic
Q52579594	Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Q98291421	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Q39008859	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
Q37947911	Response to anti-angiogenesis: an ever changing feature
Q37669383	Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity
Q93113434	Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse
Q81890232	Rhinitis and epistaxis in patients treated by anti-angiogenic therapy
Q42158334	RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA.
Q37917796	Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
Q58729601	Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
Q36301449	Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
Q35691234	Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death
Q42433181	Risks associated with sunitinib use and monitoring to improve patient outcomes
Q48365671	Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Q50586476	Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.
Q89835342	Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
Q37651091	Role of endothelial cell-selective adhesion molecule in hematogeneous metastasis
Q34254595	Role of pancreatic stellate cells in pancreatic cancer metastasis.
Q33352793	Role of placenta growth factor in cancer and inflammation
Q38399886	Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma
Q39552934	Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells
Q37228059	Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Q33740510	SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level
Q39521060	SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo
Q39521937	SPIO-RGD nanoparticles as a molecular targeting probe for imaging tumor angiogenesis using synchrotron radiation
Q36394326	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Q36860502	Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
Q38066186	Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors
Q38824719	Safety of available treatment options for renal cell carcinoma
Q37903602	Safety of bevacizumab in patients with metastatic breast cancer
Q35983858	Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis
Q38709612	Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis
Q28077612	Sanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current Uses
Q34477717	ScFv anti-heparan sulfate antibodies unexpectedly activate endothelial and cancer cells through p38 MAPK: implications for antibody-based targeting of heparan sulfate proteoglycans in cancer
Q36059674	Selective blockade of tumor angiogenesis
Q34682223	Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors
Q38546474	Selective use of vandetanib in the treatment of thyroid cancer
Q28650150	Semantically linking in silico cancer models
Q38161405	Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression
Q39334060	Serotonin activates angiogenic phosphorylation signaling in human endothelial cells
Q34606479	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy
Q35848075	Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis
Q45885224	Shortened ALK1 regulatory fragment maintains a specific activity in arteries feeding ischemic tissues
Q27324518	Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response
Q54578853	Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.
Q42263067	Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents
Q33351178	Solving the puzzle of metastasis: the evolution of cell migration in neoplasms
Q47126334	Sorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report
Q51929209	Spheroid-based human endothelial cell microvessel formation in vivo.
Q37655585	State of the art in anti-cancer mAbs.
Q38046514	Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer
Q38015229	Strategies for the discovery and development of therapies for metastatic breast cancer
Q37620640	Suppression of tumor angiogenesis by targeting the protein neddylation pathway
Q39506220	Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo.
Q33421361	Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study
Q35783198	Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity
Q33392869	Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues
Q64100389	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Q28477256	Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole
Q39800101	Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
Q47860855	Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents.
Q38062459	Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
Q33526062	TAF6delta orchestrates an apoptotic transcriptome profile and interacts functionally with p53.
Q35787916	TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types
Q38074430	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?
Q28082828	Targeted immune therapy of ovarian cancer
Q34040956	Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Q34878868	Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action
Q34088696	Targeted therapies in renal cell cancer: recent developments in imaging
Q37341824	Targeted therapy in gastric cancer.
Q47640411	Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review
Q92446657	Targeting Angiogenesis in Prostate Cancer
Q38633308	Targeting HER 2 and angiogenesis in gastric cancer
Q38964908	Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Q38799268	Targeting acid sphingomyelinase with anti-angiogenic chemotherapy
Q38053680	Targeting angiogenesis as a promising modality for the treatment of prostate cancer
Q89953634	Targeting angiogenesis in gastrointestinal tumors: current challenges
Q38389997	Targeting angiogenesis in lung cancer - Pitfalls in drug development
Q51732175	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.
Q37563976	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Q29547395	Targeting cancer with small molecule kinase inhibitors
Q34393461	Targeting the PDGF signaling pathway in tumor treatment
Q34200930	Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis.
Q36626921	Targeting the tumour microenvironment in ovarian cancer
Q37767356	Targeting the tumour vasculature: insights from physiological angiogenesis
Q37359115	Targeting tumor angiogenesis with histone deacetylase inhibitors
Q38118388	Targeting tyrosine-kinases in ovarian cancer
Q28743072	Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism
Q58112882	Taxifolin, a natural flavonoid interacts with cell cycle regulators causes cell cycle arrest and causes tumor regression by activating Wnt/ β -catenin signaling pathway
Q46407140	Ten years of anti-vascular endothelial growth factor therapy
Q42831001	Testin is a tumor suppressor and prognostic marker in breast cancer
Q33387704	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Q51745752	The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis.
Q46358843	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer
Q38679301	The Microenvironment of Lung Cancer and Therapeutic Implications
Q89724959	The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment
Q52719266	The Platelet Lifeline to Cancer: Challenges and Opportunities.
Q59793680	The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer
Q50932310	The Role of Angiogenesis in Cancer Treatment.
Q35654391	The Vital Role of Blood Flow-Induced Proliferation and Migration in Capillary Network Formation in a Multiscale Model of Angiogenesis
Q45230734	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials
Q37725449	The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.
Q35626139	The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells
Q37206338	The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis
Q36827736	The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
Q37987661	The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities
Q34312566	The characteristics of bone marrow-derived endothelial progenitor cells and their effect on glioma
Q93266252	The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials
Q34669361	The complexities of obesity and diabetes with the development and progression of pancreatic cancer
Q42434225	The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells
Q37374031	The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process?
Q61803634	The effect of cycling hypoxia on MCF-7 cancer stem cells and the impact of their microenvironment on angiogenesis using human umbilical vein endothelial cells (HUVECs) as a model
Q59793761	The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks
Q51533513	The effects of a picosecond pulsed electric field on angiogenesis in the cervical cancer xenograft models.
Q55083555	The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Q92568034	The endothelial tip-stalk cell selection and shuffling during angiogenesis
Q33559661	The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development
Q55002211	The heterogenic tumor microenvironment of hepatocellular carcinoma and prognostic analysis based on tumor neo-vessels, macrophages and α-SMA.
Q37613407	The immune system in the pathogenesis of ovarian cancer
Q26824086	The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review
Q34988362	The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer
Q38028791	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies
Q44603401	The mRNA expression of various angiogenesis-related genes in pediatric sarcomas and nonmalignant lesions of tissue
Q38243969	The miRNA network: micro-regulator of cell signaling in cancer
Q37821229	The molecular biology of head and neck cancer
Q44622914	The multitasking role of macrophages in Stanford type A acute aortic dissection.
Q28387803	The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils
Q38603771	The potential of cell sheet technique on the development of hepatocellular carcinoma in rat models.
Q36630478	The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.
Q90911537	The pro-tumorigenic host response to cancer therapies
Q37088087	The prothrombotic activity of cancer cells in the circulation
Q51791363	The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
Q37683553	The role IL-1 in tumor-mediated angiogenesis
Q37486241	The role of Notch and gamma-secretase inhibition in an ovarian cancer model
Q37833645	The role of bevacizumab in colorectal cancer: understanding its benefits and limitations
Q45222224	The role of bone marrow-derived cells during the bone healing process in the GFP mouse bone marrow transplantation model.
Q38099238	The role of functional imaging in the era of targeted therapy of renal cell carcinoma
Q55019858	The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment.
Q39096266	The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
Q38205134	The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline
Q39337947	The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer
Q34612059	The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma
Q39378690	The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women
Q33559711	The therapeutic promise of the cancer stem cell concept
Q39500842	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
Q37318832	The tumor microenvironment and its contribution to tumor evolution toward metastasis
Q34343645	The tumor microenvironment in colorectal carcinogenesis
Q52935906	The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity.
Q35618768	Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Q38805228	Therapeutic angiogenesis using tumor cell-conditioned medium.
Q47553195	Therapeutic efficacy of a synthetic epsin mimetic peptide in glioma tumor model: uncovering multiple mechanisms beyond the VEGF-associated tumor angiogenesis
Q97692561	Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
Q28253120	Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy
Q47134647	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Q33862570	Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT).
Q33810438	Three-dimensional micro-MRI analysis of cerebral artery development in mouse embryos
Q30588927	Three-dimensional reconstruction of neovasculature in solid tumors and basement membrane matrix using ex vivo X-ray microcomputed tomography
Q36113958	Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).
Q39540184	Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis
Q33887928	Tissue-engineered three-dimensional tumor models to study tumor angiogenesis.
Q37908815	Towards tailored therapy of glioblastoma multiforme
Q34612724	Tracking dynamic microvascular changes during healing after complete biopsy punch on the mouse pinna using optical microangiography.
Q38858806	Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.
Q30499092	Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors
Q36953476	Treatment of pediatric brain tumors
Q37574433	Treatment of retinal diseases with VEGF antagonists
Q49283018	Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials
Q28482576	Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts
Q37578166	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
Q36428702	Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Q36535215	Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs.
Q90478015	Tumor endothelial marker 8 promotes cancer progression and metastasis
Q39912324	Tumor metabolism: cancer cells give and take lactate
Q38057420	Tumor vasculature: the Achilles' heel of cancer?
Q36499639	Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy
Q91386068	Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma
Q37416806	Tumoral angiogenesis and breast cancer
Q34497992	Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide
Q38199737	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer
Q38205041	Understanding the biology of reactive oxygen species and their link to cancer: NADPH oxidases as novel pharmacological targets.
Q38066182	Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab.
Q34348270	Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib
Q39570902	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
Q37947558	Ups and downs of guided vessel sprouting: the role of polarity
Q35691033	Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma
Q55194696	VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia.
Q37951859	VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer.
Q92229613	VEGF in Signaling and Disease: Beyond Discovery and Development
Q33573974	VEGF inhibition and metastasis: possible implications for antiangiogenic therapy
Q37264085	VEGF inhibitors and prostate cancer therapy
Q36216197	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations
Q26770678	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
Q34420871	VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer
Q37035757	VEGF-A splicing: the key to anti-angiogenic therapeutics?
Q38982626	VEGF-C and TGF-β reciprocally regulate mesenchymal stem cell commitment to differentiation into lymphatic endothelial or osteoblastic phenotypes
Q41900132	VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2
Q38232368	VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs
Q46202577	VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
Q54118788	Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor.
Q38236623	Vandetanib as a potential treatment for breast cancer.
Q38821641	Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells
Q39691814	Vascular Mimicry: The Next Big Glioblastoma Target
Q36286704	Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
Q35227644	Vascular endothelial growth factor in anterior chamber liquid patients with diabetic retinopathy, cataract and neovascular glaucoma
Q37785877	Vascular endothelial growth factor inhibitors in malignant gliomas.
Q54012562	Vascular endothelial growth factor signaling in injured nerves underlies peripheral sensitization in neuropathic pain.
Q37695468	Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care
Q38266022	Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside
Q37117805	Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth
Q41096029	Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.
Q42750671	Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
Q37407384	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Q92059895	Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice
Q44699541	Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis
Q92267228	Whole-lesion ADC histogram analysis is not able to reflect microvessel density in HNSCC
Q38410647	Why some tumours trigger neovascularisation and others don't: the story thus far.
Q37840101	XL184 (cabozantinib) for medullary thyroid carcinoma.
Q34658579	Ziv-aflibercept in metastatic colorectal cancer
Q38152887	Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer
Q54566371	[The study of PI3K/AKT pathway in lung cancer metastasis and drug resistance].
Q39056231	hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer
Q33910328	microRNAs and lung cancer: tumors and 22-mers.
Q37468744	p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment
Q37241367	αB-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target
Q36848635	β -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells
Q35604861	γ-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1.

scholarly article	Q13442814
review article	Q7318358

P356	DOI	10.1056/NEJMRA0706596
P8608	Fatcat ID	release_xben6afysngujeu6jnmhocusky
P3181	OpenCitations bibliographic resource ID	2489563
P932	PMC publication ID	4542009
P698	PubMed publication ID	18463380
P5875	ResearchGate publication ID	5389019

P2093	author name string	Kerbel RS
P2860	cites work	Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth	Q24293042
		Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels	Q24299513
		Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis	Q24306415
		G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells	Q78312502
		Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice	Q79857937
		The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth	Q80212331
		Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition	Q80376810
		Vascular leukocytes contribute to tumor vascularization	Q80546906
		Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis	Q81277909
		VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells	Q82264553
		Antiangiogenic therapy: a universal chemosensitization strategy for cancer?	Q83854395
		Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity	Q24561642
		Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization	Q24673319
		Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors	Q24676378
		Prospective identification of tumorigenic breast cancer cells	Q24683474
		Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting	Q24685542
		Targeting HIF-1 for cancer therapy	Q27860504
		Tumor angiogenesis: therapeutic implications	Q27860595
		Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer	Q27860681
		A cell initiating human acute myeloid leukaemia after transplantation into SCID mice	Q28131777
		Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis	Q28264314
		Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer	Q28278736
		Sorafenib in advanced clear-cell renal-cell carcinoma	Q28282767
		Isolation of putative progenitor endothelial cells for angiogenesis	Q28302884
		Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer	Q28376841
		Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1	Q28469224
		Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2	Q28570936
		Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy	Q29547379
		Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene	Q29547732
		Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele	Q29547733
		A perivascular niche for brain tumor stem cells	Q29614276
		Angiogenesis: an organizing principle for drug discovery?	Q29614538
		Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors	Q29615445
		Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor	Q29617062
		Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis	Q29620559
		Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer	Q29622818
		Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.	Q33226862
		Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes	Q33371036
		Clinical translation of angiogenesis inhibitors	Q34152769
		Chemokines direct endothelial progenitors into tumor neovessels	Q34212748
		Endogenous inhibitors of angiogenesis.	Q34419511
		Autocrine VEGF signaling is required for vascular homeostasis	Q34443661
		Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis	Q34928194
		VEGF and the quest for tumour angiogenesis factors	Q34932327
		The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.	Q35028641
		Rapid vascular regrowth in tumors after reversal of VEGF inhibition	Q35052385
		The anti-angiogenic basis of metronomic chemotherapy	Q35788112
		Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients	Q46781791
		Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma	Q46837791
		Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.	Q50754378
		Effect of p53 status on tumor response to antiangiogenic therapy.	Q51726544
		Tumor-associated macrophages press the angiogenic switch in breast cancer.	Q51984236
		Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.	Q53921302
		A cancer drug shows promise, at a price that many can't pay.	Q54023421
		Contribution of bone marrow–derived endothelial cells to human tumor vasculature	Q57413787
		Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis	Q59276609
		Tumor response to radiotherapy regulated by endothelial cell apoptosis	Q73401346
		Cancer research. Mutant stem cells may seed cancer	Q73906477
		Tumor induction of VEGF promoter activity in stromal cells	Q77349243
		Vascular-targeting therapies for treatment of malignant disease.	Q35805639
		Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.	Q35848435
		Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy	Q35848919
		Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.	Q35943388
		Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.	Q36014526
		Genes that distinguish physiological and pathological angiogenesis	Q36087324
		Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy	Q36089148
		Disrupting tumour blood vessels	Q36146900
		VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade	Q36276765
		How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy	Q36328747
		Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis	Q36335555
		Lessons from phase III clinical trials on anti-VEGF therapy for cancer	Q36366446
		The role of neuropilins in cancer	Q36491431
		Predicting benefit from anti-angiogenic agents in malignancy	Q36534760
		Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.	Q36611325
		Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer	Q36613812
		The multifaceted circulating endothelial cell in cancer: towards marker and target identification.	Q36621435
		The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review	Q36650719
		Angiogenesis and antiangiogenic therapy in hematologic malignancies.	Q36692235
		Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies	Q36737772
		Molecular basis for sunitinib efficacy and future clinical development	Q36906667
		Targeting endothelial and tumor cells with semaphorins	Q36928030
		Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells	Q36929562
		Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?	Q36932941
		Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development.	Q37594746
		Bv8 regulates myeloid-cell-dependent tumour angiogenesis	Q40038500
		Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.	Q40100311
		Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors	Q40144623
		Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis	Q40191484
		Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis	Q40191493
		Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.	Q40228810
		Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models	Q40340358
		Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option	Q40511146
		Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.	Q40514698
		Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal	Q40848490
		The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis	Q42411644
		VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism	Q44043571
		Signaling vascular morphogenesis and maintenance	Q45058276
		Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.	Q45866300
		Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia	Q46114146
P433	issue	19
P407	language of work or name	English	Q1860
P921	main subject	angiogenesis inhibitor	Q574834
		neoplasm	Q1216998
		neovascularization	Q1281049
		VEGF receptors	Q4356503
		vascular endothelial growth factor A	Q7916455
		tumor angiogenesis	Q110495869
P5008	on focus list of Wikimedia project	ScienceSource	Q55439927
P304	page(s)	2039-49
P577	publication date	2008-05-08
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Tumor angiogenesis
P478	volume	358

Tumor angiogenesis

scientific article (publication date: 8 May 2008)

Reverse relations